Synnovation Therapeutics
Chris Walker is an accomplished professional in the field of clinical development, currently serving as Executive Director at Synnovation Therapeutics since May 2024. Prior experience includes roles as Vice President and Clinical Development Scientist at Immuneering Corporation from July 2021 to January 2024, and various positions at Incyte from March 2012 to July 2021, including Director and Associate Director of Clinical Development. Additional experience encompasses management of clinical research at PharmaNet Development Group, Inc. and study delivery operations at AstraZeneca. Chris Walker earned a Bachelor of Science degree in Biology from Syracuse University, graduating in 1993.
This person is not in any teams
Synnovation Therapeutics
Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers.It is dedicated to the discovery and development of therapeutics that can improve the lives of people with cancer. Leveraging its deep expertise in medicinal chemistry, cancer biology, andpatient-focused precision medicine, it builds a diverse pipeline of novel small molecule targeted therapies. It aims to efficiently advance these agents into clinical trials with the goal of transforming cancer patient care.